In 2004, 28.5% of enterococcal healthcare acquired infections (HAIs) in patients in the ICU were vancomycin resistant. From 1998-2003, the percentage of enterococcal HAIs due to vancomycin resistant enterococci increased by 12%.1

“Published estimates of the attributable cost of VRE bacteremia have ranged from $18,000 to $79,559.”2

“The BD GeneOhm™ VanR assay is considerably faster than culture.”3

---

The BD GeneOhm™ line of products has been developed to help improve patient outcomes by delivering cost-effective, rapid molecular solutions for the prevention and identification of healthcare-associated infections (HAIs).

BD GeneOhm™ VanR Assay

Assay Features:

- Lab results in <2 hours for vancomycin resistance
- Aids in the rapid identification and differentiation of both vanA and vanB genes direct from perianal and/or rectal swabs
  - vanA and vanB are clinically relevant genes associated with vancomycin-resistant enterococci.
  - These genes are transferrable from organism to organism.
- Simple, user-friendly work flow
  - Less time and labour required when compared to traditional culture methods.

Clinical Advantages:

- Rapid identification of vancomycin-resistant organisms
- Facilitates early infection control intervention to prevent transmission and infection
- Prevention of VRE transmission and infection can save healthcare costs by decreasing hospital length of stay and the need for contact precautions

"VRE infections are important because of rapid spread, prolongation of hospital stay, greater difficulty achieving satisfactory therapy, and higher attributable mortality." 5

The BD GeneOhm™ VanR Assay is the latest addition to our expanding menu of assays, extending our ability to help you identify and prevent HAIs.

© BD GeneOhm™ VanR Assay 2008  Patent protection pending
BD GeneOhm™ VanR is licensed for human diagnostics under patents or patent applications owned by Molecular Probes
BD, BD logo and all other trademarks are property of Becton, Dickinson and Company.
Copyright © 2007 BD